[BEHTYL LABORATORIES]: Profile immune checkpoints in the tumor microenvironment

Immune checkpoints are inhibitory proteins that control the strength and duration of T-cell responses. Tumor cells take advantage of these pathways to escape immune surveillance. Checkpoint inhibitors can stimulate the immune system to eliminate tumors, as shown with FDA-approved therapeutics targeting CTLA-4 and PD-1.

Characterizing both inhibitory and stimulatory molecules that control T-cell response can inform efforts to develop effective immunotherapies.

Search our comprehensive portfolio of validated Bethyl antibodies to facilitate checkpoint research, including PD-L1, LAG3, TIM3, and OX40/CD134.